Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - hestaværur; hundahár; kattahár - húðstungupróf, lausn - 10 hep

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - dermatophagoides pteronyssinus; dermatophagoides farinae - húðstungupróf, lausn - 10 hep

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - corylus avellana; alnus glutinosa (alder); alnus incana; betula verrucosa - húðstungupróf, lausn - 10 hep

Unione Europea - islandese - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakónazól - candidiasis; mycoses; coccidioidomycosis; aspergillosis - sveppalyf fyrir almenn nota - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Unione Europea - islandese - EMA (European Medicines Agency)

gilead sciences ireland uc - aztreonam lysín - cystic fibrosis; respiratory tract infections - sýklalyf fyrir almenn nota, - cayston er ætlað fyrir bælandi meðferð langvarandi lungum sýkingum vegna pseudomonas tilhneiging til að hætta í sjúklingar fengið lungnasjúkdóm (samanber) aldrinum 6 ára og eldri. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Unione Europea - islandese - EMA (European Medicines Agency)

virbac s.a. - leishmania infantum skilst út seytta prótein - Ónæmisfræðilegar upplýsingar - hundar - fyrir virka bólusetningu leishmania-neikvæðra hunda frá sex mánaða aldri til að draga úr hættu á að mynda virkan sýkingu og klínískan sjúkdóm eftir snertingu við leishmania infantum. sýnt hefur verið fram á verkun bóluefnisins hjá hundum sem höfðu verið fyrir ýmsum náttúrulegum sníkjudýrum útsetningu á svæðum með mikla sýkingarþrýsting. upphaf ónæmis: 4 vikum eftir grunnbólusetningu. lengd ónæmis: 1 ár eftir síðustu bólusetningu.

Unione Europea - islandese - EMA (European Medicines Agency)

intervet international bv - lifandi eyðing-stökkbreytt streptococcus equi stofn tw928 - Ónæmisfræðilegar upplýsingar fyrir hófdýr - hestar - fyrir ónæmisaðgerðir hesta gegn streptococcus equi til að draga úr klínískum einkennum og tilkomu eitlafrumukrabbameins. upphaf ónæmis: upphaf ónæmis er staðfest sem tveggja vikna eftir grunnbólusetningu. lengd ónæmis: lengd ónæmis er í allt að þrjá mánuði. bóluefnið er ætlað til notkunar hjá hestum þar sem hætta hefur verið á streptococcus equi sýkingu, vegna snertingar við hesta frá svæðum þar sem þessi sýkill er vitað að vera til staðar, e. hesthús með hesta sem ferðast til sýninga eða keppna á slíkum svæðum, eða hesthúsum sem fá eða hafa lifandi hesta frá slíkum svæðum.

Unione Europea - islandese - EMA (European Medicines Agency)

laboratorios hipra, s.a. - bóluefni gegn hníslalyfjum í kjúklingum - lifandi sníkjudýra bóluefni, Ónæmislyf fyrir aves - kjúklingur - fyrir virk bólusetningar kjúklinga frá 1 dag aldri til að draga úr klínískum merki (niðurgangur), þarma sár og eaablöðrur framleiðsla tengslum við hníslasótt af völdum eimeria acervulina, eimeria brunetti, eimeria maxima, eimeria necatrix og eimeria tenella.

Unione Europea - islandese - EMA (European Medicines Agency)

intervet international bv - lifðu bordetella bronchiseptica bakteríur álag b-c2 - Ónæmislyf fyrir felidae, - kettir - fyrir virkan ónæmingu katta, sem eru 1 mánaða eða eldri, til að draga úr klínískum einkennum bordetella bronchiseptica tengda sjúkdóma í efri öndunarvegi. upphaf ónæmis: upphaf ónæmis var stofnað í 8 vikna ketti eins fljótt og 72 klukkustundum eftir bólusetningu. lengd ónæmis: lengd ónæmis er allt að 1 ár. engar upplýsingar liggja fyrir um áhrif mótefna mótefna á áhrifum bólusetningar með nobivac bb fyrir ketti. frá bókmenntum er talið að þessi tegund bóluefnis í innrennsli geti valdið ónæmissvörun án truflunar frá mótefnum sem myndast mótefni.

Unione Europea - islandese - EMA (European Medicines Agency)

intervet international bv - lifandi myxoma-vectored kanína-blæðandi-sjúkdóm afbrigði veirunnar 009 - Ónæmisfræðilegar upplýsingar - kanínur - fyrir virkan ónæmisaðgerð kanína frá fimm vikna aldri til að draga úr dánartíðni og klínískum einkennum af völdum myxomatosis og til að koma í veg fyrir dánartíðni vegna blæðingar frá kanínum. upphaf ónæmis: 3 vikur. lengd ónæmis: 1 ár.